Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

NCT03668522 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-09-12

No results posted yet for this study

Summary

H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.

Conditions

  • Spinal Tumor

Interventions

OTHER

Genetic testing

To determine whether H3F3AK27M exist in spinal glioma

Sponsors & Collaborators

  • Southern Medical University, China

    lead OTHER

Principal Investigators

  • Lu Yuntao, M.D., Ph.D · Nanfang Hospital Neurosurgery Department

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03668522 on ClinicalTrials.gov